Leflunomide Tablet
Product Images NDC 71335-2832

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 71335-2832). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image
Avet-logo (Avet Logo)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A bar chart showing the percentage of ACR 20 responders at study endpoints across three clinical trials of 6 to 12 months. The chart compares response rates for leflunomide, methotrexate, placebo, and sulfasalazine, with percentage values on the vertical axis and trial numbers with durations on the horizontal axis.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over 12 months. Three treatment groups are compared: PL, MTX, and LEF, each represented by distinct markers. The Y-axis indicates percentage responders, while the X-axis shows time in months. LEF shows generally higher response rates over time compared to PL and MTX.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A bar chart titled 'Change in Sharp Score' displaying data from three trials over different durations (12 months and 6 months). The chart compares progression scores for treatments labeled L (Leflunomide), M (Methotrexate), S (Sulfasalazine), and P (Placebo). Bars indicate varying levels of progression and improvement across treatments with numeric values under each bar.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A bar chart titled 'Change in Functional Ability Measure,' comparing trials over 6 to 12 months. It shows functional improvement changes with leflunomide (L), methotrexate (M), placebo (P), and sulfasalazine (S) based on the HAQ Disability Index. The Y-axis ranges from 0.2 to -0.6, indicating degrees of improvement.*
FDA Label Image

Label (Lbl713352832)

Label (Lbl713352832)
Leflunomide Tablets, USP 20 mg label showing NDC 71335-2832-1. The label indicates a bottle containing 30 tablets, Rx only, manufactured by Heritage Pharma Labs Inc. and relabeled by Bryant Ranch Prepack, Inc. It includes storage instructions, a warning to keep out of reach of children, and QR codes for package insert and prescribing information.*
FDA Label Image

Structural-formula (Structural Formula)

Structural-formula (Structural Formula)
Chemical structure diagram of leflunomide showing its molecular composition with labeled atoms and bonds, including characteristic rings and functional groups.*
FDA Label Image

Teriflunomide-structural-formula. (Teriflunomide Structural Formula)

Teriflunomide-structural-formula. (Teriflunomide Structural Formula)
Chemical structure of leflunomide (teriflunomide) depicted with molecular bonds and functional groups including trifluoromethyl, amide, and nitrile groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.